BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...testing for atherosclerosis and Phase I testing for renal diseases and AD. Two other companies, Dybly AG...
...Celgene Corp. (NASDAQ:CELG), Summit, N.J. Chroma Therapeutics Ltd., Abingdon, U.K. Constellation Pharmaceuticals Inc., Cambridge, Mass. Dybly AG...
BioCentury | Oct 30, 2014
Cover Story

Redistributing BRD4 in inflammation

...in Phase II testing for diabetes and in Phase I trials for Alzheimer's disease (AD). Dybly AG...
...view in atherosclerosis The study results also could help guide BET inhibitor programs in development. Dybly...
...can also induce regression of established plaques, which is more clinically relevant. Kempen said that Dybly...
Items per page:
1 - 2 of 2
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...testing for atherosclerosis and Phase I testing for renal diseases and AD. Two other companies, Dybly AG...
...Celgene Corp. (NASDAQ:CELG), Summit, N.J. Chroma Therapeutics Ltd., Abingdon, U.K. Constellation Pharmaceuticals Inc., Cambridge, Mass. Dybly AG...
BioCentury | Oct 30, 2014
Cover Story

Redistributing BRD4 in inflammation

...in Phase II testing for diabetes and in Phase I trials for Alzheimer's disease (AD). Dybly AG...
...view in atherosclerosis The study results also could help guide BET inhibitor programs in development. Dybly...
...can also induce regression of established plaques, which is more clinically relevant. Kempen said that Dybly...
Items per page:
1 - 2 of 2